Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.
@article{Js1995SaquinavirF, title={Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.}, author={James Js}, journal={AIDS treatment news}, year={1995}, pages={1-2} }
: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the Food and Drug Administration (FDA) for use in combination with one or more unspecified nucleoside analogs. Rifampin should not be taken with saquinavir, and rifabutin should be only cautiously used in combination with saquinavir. Protease inhibitors have shown T-cell increases and viral load reductions similar to AZT when taken at the present low dosage. Research is… CONTINUE READING
Topics from this paper
7 Citations
Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
- Medicine
- Current topics in medicinal chemistry
- 2019
- 13
HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors
- Computer Science, Medicine
- Journal of Cheminformatics
- 2018
- 8
- PDF
Saquinavir‐NO Inhibits IL‐6 Production in Macrophages
- Biology, Medicine
- Basic & clinical pharmacology & toxicology
- 2014
- 3
Trends in Mortality From Human Immunodeficiency Virus Infection, 1984-2016: An Autopsy-Based Study.
- Medicine
- Archives of pathology & laboratory medicine
- 2019
- 5
[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
- Biology, Medicine
- Medecine sciences : M/S
- 2020